MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-13-2026
Takeda Pharmaceutical Company Limited General and Administrative Expenses 2011-2026 | TAK
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Takeda Pharmaceutical Company Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 965 B | 718 B | 628 B | 619 B | 651 B | 613 B | 556 B | 812 B | 811 B | 640 B |
All numbers in JPY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 965 B | 556 B | 701 B |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
2.31 M | - | 1.35 % | $ 17.8 M |  China |
 |
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 7.14 | 1.56 % | $ 196 M |  Israel |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
514 M | $ 93.13 | 1.07 % | $ 22.5 B | Germany |
 |
AstraZeneca PLC
AZN
|
19.9 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Compugen Ltd.
CGEN
|
8.89 M | $ 2.71 | -3.16 % | $ 253 M | Israel |
 |
Abcam plc
ABCM
|
224 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
24.7 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
10.5 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
17 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
7.72 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
30.7 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
139 M | - | - | $ 3.37 B | China |
 |
Coherus BioSciences
CHRS
|
101 M | $ 1.68 | 4.04 % | $ 197 M | USA |
 |
Anika Therapeutics
ANIK
|
49.1 M | $ 14.64 | -1.61 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.46 | 1.74 % | $ 5.7 M | Israel |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
38.8 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 21.02 | 0.77 % | $ 2.67 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |